These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32570169)

  • 1. Effects of perampanel on secondary bilateral synchrony and behavioral problems in adolescents with epilepsy showing insufficient response with levetiracetam.
    Kanemura H; Sano F; Hoshino H; Takayama K; Aihara M
    Seizure; 2020 Aug; 80():131-137. PubMed ID: 32570169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of levetiracetam on seizure frequency and neuropsychological impairments in children with refractory epilepsy with secondary bilateral synchrony.
    Kanemura H; Sano F; Sugita K; Aihara M
    Seizure; 2013 Jan; 22(1):43-7. PubMed ID: 23127775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of perampanel in epilepsy patients with autism spectrum disorder.
    Kanemura H; Sano F; Hoshino H; Aihara M
    Epilepsy Res; 2021 Feb; 170():106550. PubMed ID: 33450524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy.
    Kanemura H; Sano F; Ohyama T; Sugita K; Aihara M
    Eur J Paediatr Neurol; 2014 Jul; 18(4):482-8. PubMed ID: 24703761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of levetiracetam efficacy in epileptic syndromes with continuous spikes-waves during slow sleep.
    Atkins M; Nikanorova M
    Seizure; 2011 Oct; 20(8):635-9. PubMed ID: 21752673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy.
    Kanemura H; Sano F; Aihara M
    Eur J Paediatr Neurol; 2019 Jan; 23(1):197-203. PubMed ID: 30424990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: experience in 12 cases.
    Aeby A; Poznanski N; Verheulpen D; Wetzburger C; Van Bogaert P
    Epilepsia; 2005 Dec; 46(12):1937-42. PubMed ID: 16393159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
    Ben-Menachem E; Gilland E
    Seizure; 2003 Apr; 12(3):131-5. PubMed ID: 12651076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add-on therapy compared to levetiracetam and valproic acid.
    Liguori C; Turner K; Izzi F; Assogna M; Canevini MP; Mercuri NB; Placidi F
    CNS Neurosci Ther; 2019 May; 25(5):632-637. PubMed ID: 30675751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
    Chonan M; Saito R; Kanamori M; Osawa SI; Watanabe M; Suzuki H; Nakasato N; Tominaga T
    Neurol Med Chir (Tokyo); 2020 Jan; 60(1):37-44. PubMed ID: 31748440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Strategies in Children with Epilepsy: A Quality-of-Life-Related Perspective.
    Kanemura H
    J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256539
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
    Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
    Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the anticonvulsant activity of levetiracetam dose-dependent?
    Lamouret V; Kurth C; Intravooth T; Steinhoff BJ
    Seizure; 2020 Dec; 83():197-202. PubMed ID: 33197757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychiatric and behavioral concerns of perampanel with concomitant levetiracetam in children with epilepsy.
    Kim JS; Kim WS; Sung WY; Woo H
    Epilepsy Behav; 2024 May; 154():109740. PubMed ID: 38547767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of the initial efficacy of levetiracetam in patients with refractory epilepsy.
    Lee GH; Kim BM; Kang JK; Lee SA
    Seizure; 2013 Apr; 22(3):185-8. PubMed ID: 23280273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study.
    Liguori C; Izzi F; Manfredi N; D'Elia A; Mari L; Mercuri NB; Fabio P
    Epilepsy Behav; 2018 Mar; 80():173-176. PubMed ID: 29414548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy.
    Kanemura H; Sano F; Tando T; Sugita K; Aihara M
    Brain Dev; 2013 May; 35(5):386-91. PubMed ID: 22871391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levetiracetam for people with mental retardation and refractory epilepsy.
    Kelly K; Stephen LJ; Brodie MJ
    Epilepsy Behav; 2004 Dec; 5(6):878-83. PubMed ID: 15582836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levetiracetam as add-on therapy in different subgroups of "benign" idiopathic focal epilepsies in childhood.
    von Stülpnagel C; Kluger G; Leiz S; Holthausen H
    Epilepsy Behav; 2010 Feb; 17(2):193-8. PubMed ID: 20045383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.